Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 832,310 | $124,388,730 | 3.56% | |
| 2. | 500,000 | $74,725,000 | 6.04% | ||
| 3. | Casdin Capital Eli Casdin | 358,000 | $53,503,100 | +84% | 3.97% |
| 4. | Vestal Point Capital Ryan Wilder | 350,000 | $52,307,500 | +900% | 4.32% |
| 5. | VenBio Select Advisor Kurt Von Emster | 300,000 | $44,835,000 | -73% | 0.52% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.87 | 297,501 | Large Shareholder | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | Officer | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | Director | 27,900 | 2016-10-13 | Filing | |
| $58.36 | 2,000 | Director | 4,000 | 2016-03-09 | Filing | |
| $69.75 | 205,030 | Large Shareholder | 10,256,633 | 2016-02-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $261.00 | 7,093 | Officer, Director | 73,441 | 2024-07-11 | Filing | |
| $240.00 | 8,500 | Director | 8,436 | 2024-06-25 | Filing | |
| $222.00 | 7,470 | Director | 136 | 2024-06-24 | Filing | |
| $221.00 | 7,420 | Director | 7,606 | 2024-06-24 | Filing | |
| $220.00 | 17,560 | Director | 15,026 | 2024-06-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,174,563 | $3,096,023,554 | 0.55% | |
| 2. | 11,943,895 | $2,286,180,943 | 0.05% | |
| 3. | 10,312,356 | $1,973,888,016 | 0.15% | |
| 4. | 8,521,115 | $1,631,026,620 | 0.04% | |
| 5. | 7,214,198 | $1,380,869,641 | 0.25% |
News See All
5 Most Promising Stocks to Buy Before They Take Off
In this article, we discuss the 5 most promising stocks to buy before they take off.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.1, expectations were $-1.2.
13 Most Promising Healthcare Stocks According to Analysts
In this article, we discuss the 13 most promising healthcare stocks according to analysts.
30 Largest Pharmaceutical Companies in the World
In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q3 2023 Earnings Conference Call. At this time, participants are in a listen-only mode.
13 Best Beaten Down Stocks To Buy Now
In this article, we will be taking a look at the 13 best beaten down stocks to buy now.
18 Best 52-Week Low Stocks To Buy Now
US stock markets are jittery after Fed Chair Jerome Powell made it clear that inflation is still high and needs further taming.
Billionaire Hedge Funds
